Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients.
Mahmoud MohammadiThekla M Jansen-WerkhovenNikki S IjzermanDide den HollanderRoos F BleckmanAstrid W OostenIngrid M E DesarAn K L ReynersNeeltje SteeghsHans GelderblomPublished in: Targeted oncology (2022)
This study represents a proper sample size cohort containing detailed data on mutational status of patients with advanced GIST. We illustrated that imatinib dose escalation could serve as a good alternative for sunitinib as second-line treatment in patients with a non-KIT exon 9 mutation.